242 related articles for article (PubMed ID: 23612011)
1. Inhibition of ron kinase blocks conversion of micrometastases to overt metastases by boosting antitumor immunity.
Eyob H; Ekiz HA; Derose YS; Waltz SE; Williams MA; Welm AL
Cancer Discov; 2013 Jul; 3(7):751-60. PubMed ID: 23612011
[TBL] [Abstract][Full Text] [Related]
2. RON promotes the metastatic spread of breast carcinomas by subverting antitumor immune responses.
Eyob H; Ekiz HA; Welm AL
Oncoimmunology; 2013 Sep; 2(9):e25670. PubMed ID: 24327933
[TBL] [Abstract][Full Text] [Related]
3. Blocking Short-Form Ron Eliminates Breast Cancer Metastases through Accumulation of Stem-Like CD4+ T Cells That Subvert Immunosuppression.
Lai SA; Gundlapalli H; Ekiz HA; Jiang A; Fernandez E; Welm AL
Cancer Discov; 2021 Dec; 11(12):3178-3197. PubMed ID: 34330779
[TBL] [Abstract][Full Text] [Related]
4. The ron receptor tyrosine kinase: a key regulator of inflammation and cancer progression.
Wang X; Hankey PA
Crit Rev Immunol; 2013; 33(6):549-74. PubMed ID: 24266348
[TBL] [Abstract][Full Text] [Related]
5. Preclinical Efficacy of Ron Kinase Inhibitors Alone and in Combination with PI3K Inhibitors for Treatment of sfRon-Expressing Breast Cancer Patient-Derived Xenografts.
Bieniasz M; Radhakrishnan P; Faham N; De La O JP; Welm AL
Clin Cancer Res; 2015 Dec; 21(24):5588-600. PubMed ID: 26289070
[TBL] [Abstract][Full Text] [Related]
6. Identification of a novel recepteur d'origine nantais/c-met small-molecule kinase inhibitor with antitumor activity in vivo.
Zhang Y; Kaplan-Lefko PJ; Rex K; Yang Y; Moriguchi J; Osgood T; Mattson B; Coxon A; Reese M; Kim TS; Lin J; Chen A; Burgess TL; Dussault I
Cancer Res; 2008 Aug; 68(16):6680-7. PubMed ID: 18701492
[TBL] [Abstract][Full Text] [Related]
7. RON kinase: A target for treatment of cancer-induced bone destruction and osteoporosis.
Andrade K; Fornetti J; Zhao L; Miller SC; Randall RL; Anderson N; Waltz SE; McHale M; Welm AL
Sci Transl Med; 2017 Jan; 9(374):. PubMed ID: 28123075
[TBL] [Abstract][Full Text] [Related]
8. Point mutations in the tyrosine kinase domain release the oncogenic and metastatic potential of the Ron receptor.
Santoro MM; Penengo L; Minetto M; Orecchia S; Cilli M; Gaudino G
Oncogene; 1998 Aug; 17(6):741-9. PubMed ID: 9715276
[TBL] [Abstract][Full Text] [Related]
9. Recepteur d'origine nantais tyrosine kinase is a direct target of hypoxia-inducible factor-1alpha-mediated invasion of breast carcinoma cells.
Thangasamy A; Rogge J; Ammanamanchi S
J Biol Chem; 2009 May; 284(21):14001-10. PubMed ID: 19307182
[TBL] [Abstract][Full Text] [Related]
10. Met-related receptor tyrosine kinase Ron in tumor growth and metastasis.
Wagh PK; Peace BE; Waltz SE
Adv Cancer Res; 2008; 100():1-33. PubMed ID: 18620091
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic implications of a human neutralizing antibody to the macrophage-stimulating protein receptor tyrosine kinase (RON), a c-MET family member.
O'Toole JM; Rabenau KE; Burns K; Lu D; Mangalampalli V; Balderes P; Covino N; Bassi R; Prewett M; Gottfredsen KJ; Thobe MN; Cheng Y; Li Y; Hicklin DJ; Zhu Z; Waltz SE; Hayman MJ; Ludwig DL; Pereira DS
Cancer Res; 2006 Sep; 66(18):9162-70. PubMed ID: 16982759
[TBL] [Abstract][Full Text] [Related]
12. Regulation of the RON receptor tyrosine kinase expression in macrophages: blocking the RON gene transcription by endotoxin-induced nitric oxide.
Wang MH; Fung HL; Chen YQ
J Immunol; 2000 Apr; 164(7):3815-21. PubMed ID: 10725742
[TBL] [Abstract][Full Text] [Related]
13. The RON receptor tyrosine kinase promotes metastasis by triggering MBD4-dependent DNA methylation reprogramming.
Cunha S; Lin YC; Goossen EA; DeVette CI; Albertella MR; Thomson S; Mulvihill MJ; Welm AL
Cell Rep; 2014 Jan; 6(1):141-54. PubMed ID: 24388747
[TBL] [Abstract][Full Text] [Related]
14. Tumor cell intrinsic RON signaling suppresses innate immune responses in breast cancer through inhibition of IRAK4 signaling.
Bourn JR; Ruiz-Torres SJ; Hunt BG; Benight NM; Waltz SE
Cancer Lett; 2021 Apr; 503():75-90. PubMed ID: 33508385
[TBL] [Abstract][Full Text] [Related]
15. Macrophage-stimulating protein, the ligand for the stem cell-derived tyrosine kinase/RON receptor tyrosine kinase, inhibits IL-12 production by primary peritoneal macrophages stimulated with IFN-gamma and lipopolysaccharide.
Morrison AC; Wilson CB; Ray M; Correll PH
J Immunol; 2004 Feb; 172(3):1825-32. PubMed ID: 14734766
[TBL] [Abstract][Full Text] [Related]
16. Knockdown of Ron kinase inhibits mutant phosphatidylinositol 3-kinase and reduces metastasis in human colon carcinoma.
Wang J; Rajput A; Kan JL; Rose R; Liu XQ; Kuropatwinski K; Hauser J; Beko A; Dominquez I; Sharratt EA; Brattain L; Levea C; Sun FL; Keane DM; Gibson NW; Brattain MG
J Biol Chem; 2009 Apr; 284(16):10912-22. PubMed ID: 19224914
[TBL] [Abstract][Full Text] [Related]
17. Regulation of macrophage arginase expression and tumor growth by the Ron receptor tyrosine kinase.
Sharda DR; Yu S; Ray M; Squadrito ML; De Palma M; Wynn TA; Morris SM; Hankey PA
J Immunol; 2011 Sep; 187(5):2181-92. PubMed ID: 21810604
[TBL] [Abstract][Full Text] [Related]
18. Activation of the RON receptor tyrosine kinase by macrophage-stimulating protein inhibits inducible cyclooxygenase-2 expression in murine macrophages.
Zhou YQ; Chen YQ; Fisher JH; Wang MH
J Biol Chem; 2002 Oct; 277(41):38104-10. PubMed ID: 12177064
[TBL] [Abstract][Full Text] [Related]
19. RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma.
Catenacci DV; Cervantes G; Yala S; Nelson EA; El-Hashani E; Kanteti R; El Dinali M; Hasina R; Brägelmann J; Seiwert T; Sanicola M; Henderson L; Grushko TA; Olopade O; Karrison T; Bang YJ; Kim WH; Tretiakova M; Vokes E; Frank DA; Kindler HL; Huet H; Salgia R
Cancer Biol Ther; 2011 Jul; 12(1):9-46. PubMed ID: 21543897
[TBL] [Abstract][Full Text] [Related]
20. Ron receptor tyrosine kinase signaling as a therapeutic target.
Benight NM; Waltz SE
Expert Opin Ther Targets; 2012 Sep; 16(9):921-31. PubMed ID: 22834780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
